Wednesday, May 25, 2011
Over 4,000 research abstracts will be presented, including important research about advances in ovarian cancer treatment and care. Below is a preview of a few of the major studies of interest to ovarian cancer patients:
• Long-Term Treatment with Olaparib May Help Treat Recurrent Ovarian Cancer
• Screening Does Not Reduce Deaths from Ovarian Cancer for the General Population
• Cabozantinib Helps Manage Several Advanced Cancers (including Ovarian) and Shrink Bone Metastases
• Genetic Variations Identify Patients Sensitive to Nerve Damage from Chemotherapy
To hear in-depth information about these studies, listen to a podcast from ASCO leaders which is alsoASCO’s patient education website.
Anesthesiology News - Blood Transfusion Speeds Recurrence of Ovarian Cancer - further research required
“There are now dozens of studies that demonstrate superior patient outcomes with restrictive transfusion practices,” Dr. Ereth said. “In general, the less blood you transfuse, the better your patient outcomes. In the future we will hopefully be able to further define the mechanisms of immune modulation with transfusion and then when transfusion is absolutely necessary, be able to design interventions to limit those effects.”
Until then, however, he stressed that efforts should be made in all clinical settings to minimize blood transfusion as much as possible.
A thesis presented to the Department of Biological Sciences – Genetic CounselingCommunication of Lynch Syndrome Genetic Test Results: Strategies to Facilitate Information Sharing with At-risk Family Members
"...Results can then be used to develop new tools such as more
patient-friendly online resources similar to those offered by the hereditary breast and
ovarian cancer organization, FORCE......"
OVARIAN CANCER: South Coast Gynecologic Oncology is enrolling women with recurrent ovarian cancer for participation in a new clinical research study, called Trinova-1. The study is open to women 18 years or older who have been diagnosed with recurrent ovarian cancer, have undergone surgery to remove at least one ovary, and have been previously treated with chemotherapy. Visit www.TRINOVA-1.com or call 858-455-5524.